<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051518</url>
  </required_header>
  <id_info>
    <org_study_id>COR-2006-02</org_study_id>
    <nct_id>NCT01051518</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Percutaneous Implantation of the Medtronic CoreValve Aortic Valve Prosthesis (18Fr-Study)</brief_title>
  <official_title>Clinical Evaluation of Percutaneous Implantation of the CoreValve Aortic Valve Prosthesis. Safety and Performance Study on Patients at High Risk for Surgical Valve Replacement (18Fr Safety and Efficacy Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigation concerns a prospective, multicenter, single arm safety and performance
      study evaluating the Medtronic CoreValve system. Approximately 120 patients presenting with
      symptomatic aortic native valve stenosis necessitating valve replacement which are considered
      poor surgical candidates, with a high surgical risk, as attested to by both the surgeon and
      the cardiologist are recruited in the study.

      Safety and performance will be evaluated at discharge and at 30 days post-procedure. Valve
      performance and placement will be followed up at 3 and 6 months post-procedure. Further
      long-term patient follow-up visits will be performed at 12, 24, 36 and 48 months
      post-procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Major Adverse Event (MAE) Free Rate</measure>
    <time_frame>30 (+7) days post procedure</time_frame>
    <description>Percentage of subjects without a composite major adverse event (MAE) at 30 (+ 7) days post-procedure. MAE included all-cause death, non-fatal myocardial infarction, stroke, emergent cardiac re-intervention, cardiac tamponade, non-structural or structural valve dysfunction, cardiogenic shock, endocarditis, TIA, embolism, aortic dissection, access site vessel dissection, vessel perforation, acute vessel occlusion, major bleeding and major vascular injury.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Technical Device Success</measure>
    <time_frame>Was assessed during the procedure and completed once the procedure was conlcluded</time_frame>
    <description>Composite technical success was defined as the percentage of subjects in whom success on all four technical measures of the &quot;Device Functionality Assessment&quot; was achieved and who were adjudicated as having no device failure or malfunction.
The four measures of the ''Device Functionality Assessment'' were:
Load the valve delivery system using the loading system
Access the aortic valve with the delivery catheter
Deploy the valve accurately across the native aortic valve
Remove the intact delivery system</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>CoreValve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic CoreValve System</intervention_name>
    <description>Transcatheter Aortic Valve</description>
    <arm_group_label>CoreValve</arm_group_label>
    <other_name>Medtronic CoreValve Trancatheter Aortic Valve</other_name>
    <other_name>Medtronic CoreValve Percutaneous Aortic Valve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Native aortic valve disease, defined as valve stenosis with an aortic valve area &lt;1cm²
             (&lt;0.6cm2/m2) as determined by echocardiographic measure,

          -  ≥ 75 years, or

          -  Surgical risk calculated with logistic EuroSCORE ≥ 15 %, or

          -  One or two (but not more than 2) of the following complicating factors:

               1. Cirrhosis of the liver (Child class A or B),

               2. Pulmonary insufficiency : Forced expiratory volume in one second (FEV1) &lt; 1
                  liter,

               3. Previous cardiac surgery (Coronary artery bypass grafting (CABG), valvular
                  surgery),

               4. Pulmonary hypertension &gt; 60 mmHg and high risk of cardiac surgery other than
                  valve replacement,

               5. Porcelain aorta

               6. Recurrent pulmonary embolus,

               7. Right ventricular insufficiency,

               8. Thoracic burning sequelae contraindicating open chest surgery,

               9. History of mediastinum radiotherapy,

              10. Severe connective tissue disease resulting in a contraindication to surgery,

              11. Cachexia (BMI ≤ 18 kg/m²),

          -  Aortic valve annulus diameter is ≥ 20 mm and ≤ 27 mm as determined by
             echocardiographic measure,

          -  Ascending aorta diameter £ 45 mm at the sino-tubular junction, and

          -  Signed Informed Consent.

        Exclusion Criteria:

          -  Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine,
             clopidogrel, Nitinol, or sensitivity to contrast media which cannot be adequately
             pre-medicated,

          -  Any sepsis, including active endocarditis,

          -  Recent myocardial infarction (&lt; 30 days),

          -  Percutaneous coronary or vascular intervention within 15 days prior to the study
             procedure, or scheduled during or within 30 days after the study procedure,

          -  Any left ventricular or atrial thrombus diagnosed by echocardiography,

          -  Uncontrolled atrial fibrillation (heart rate greater than 100 bpm),

          -  Mitral or tricuspid valvular insufficiency ( &gt; grade II),

          -  Previous aortic valve replacement (mechanical valve OR stented bioprosthetic valve),

          -  Any condition considered as contraindication for extracorporeal assistance,

          -  Evolutive or recent CVA (cerebro vascular accident),

          -  Poly arterial patients with either:

               1. Femoral, iliac or aortic vascular condition (e.g. stenosis, tortuosity), that
                  make insertion and endovascular access to the aortic valve impossible, or

               2. Symptomatic carotid or vertebral arteries narrowing (&gt; 70%) disease, or

               3. Abdominal or thoracic aortic aneurysm,

          -  Bleeding diathesis or coagulopathy, or patient who will refuse blood transfusion,

          -  Evolutive disease with life expectancy less than one year,

          -  Creatinine clearance &lt; 20 ml/min,

          -  Pregnancy, and

          -  Enrolled in another investigational study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Grube, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helios Heart Center Siegburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. Schuler, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Universitat Leipzig, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. Bonan, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cardiologie de Montreal, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Kovac, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glenfield Hospital Leicester, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. Serruys, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC Rotterdam, Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Labinaz, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ottawa Heart Institute, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P den Heijer, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amphia Hospital Breda, Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M Mullen, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton &amp; Harefield NHS Trust London, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W. Tymchak, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cardiologie de Montreal</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Heart Center Siegburg</name>
      <address>
        <city>Siegburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton &amp; Harefield NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.medtronic.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2010</study_first_posted>
  <results_first_submitted>October 27, 2017</results_first_submitted>
  <results_first_submitted_qc>February 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 19, 2019</results_first_posted>
  <last_update_submitted>February 18, 2019</last_update_submitted>
  <last_update_submitted_qc>February 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Nine sites from Western Europe and Canada enrolled 126 subjects between May 2006 and November 2008.</recruitment_details>
      <pre_assignment_details>Of 126 subjects enrolled, 124 were implanted with the CoreValve aortic valve.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>All enrolled subjects for whom the procedure of percutaneous implantation of the Medtronic CoreValve aortic valve prosthesis was started.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Overall study population was divided in high and moderate risk groups based on the risk of operative mortality. The risk classification was performed by 2 independent cardiovascular surgeons who were blinded to procedural details and outcomes but were provided with the baseline logistic EuroSCORE, baseline data and available source documentation.</population>
      <group_list>
        <group group_id="B1">
          <title>High Risk</title>
          <description>Subjects with a high risk of operative mortality.</description>
        </group>
        <group group_id="B2">
          <title>Moderate Risk</title>
          <description>Subjects with a moderate risk of operative mortality.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.3" spread="7.2"/>
                    <measurement group_id="B2" value="83.8" spread="4.9"/>
                    <measurement group_id="B3" value="82.4" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EuroSCORE</title>
          <description>Measure Description: EuroSCORE: European System for Cardiac Operative Risk Evaluation. Is a measure for predicted operative mortality for patients undergoing cardiac surgery. If a risk factor is present, a weight/number is assigned. The weights are added to give an approximate percent of predicted mortality. The resulting scores are provided on a scale ranging from 0% (no risk at all) to 100% (inoperable) .</description>
          <units>Percent of predicted operative mortality</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="14.5"/>
                    <measurement group_id="B2" value="16.1" spread="8.5"/>
                    <measurement group_id="B3" value="23.4" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA</title>
          <description>New York Heart Association (NYHA): I) No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea. II) Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea. III) Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. IV) Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NYHA class I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA class II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA class III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA class IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Major Adverse Event (MAE) Free Rate</title>
        <description>Percentage of subjects without a composite major adverse event (MAE) at 30 (+ 7) days post-procedure. MAE included all-cause death, non-fatal myocardial infarction, stroke, emergent cardiac re-intervention, cardiac tamponade, non-structural or structural valve dysfunction, cardiogenic shock, endocarditis, TIA, embolism, aortic dissection, access site vessel dissection, vessel perforation, acute vessel occlusion, major bleeding and major vascular injury.</description>
        <time_frame>30 (+7) days post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Risk</title>
            <description>Subjects with a high risk of operative mortality.</description>
          </group>
          <group group_id="O2">
            <title>Moderate Risk</title>
            <description>Subjects with a moderate risk of operative mortality.</description>
          </group>
          <group group_id="O3">
            <title>Overall Study</title>
            <description>All enrolled subjects for whom the procedure for percutaneous implantation of the Medtronic CoreValve aortic valve prosthesis was started.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Major Adverse Event (MAE) Free Rate</title>
          <description>Percentage of subjects without a composite major adverse event (MAE) at 30 (+ 7) days post-procedure. MAE included all-cause death, non-fatal myocardial infarction, stroke, emergent cardiac re-intervention, cardiac tamponade, non-structural or structural valve dysfunction, cardiogenic shock, endocarditis, TIA, embolism, aortic dissection, access site vessel dissection, vessel perforation, acute vessel occlusion, major bleeding and major vascular injury.</description>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2" lower_limit="42.0" upper_limit="66.0"/>
                    <measurement group_id="O2" value="48.1" lower_limit="34.3" upper_limit="62.2"/>
                    <measurement group_id="O3" value="51.6" lower_limit="42.5" upper_limit="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Technical Device Success</title>
        <description>Composite technical success was defined as the percentage of subjects in whom success on all four technical measures of the &quot;Device Functionality Assessment&quot; was achieved and who were adjudicated as having no device failure or malfunction.
The four measures of the ''Device Functionality Assessment'' were:
Load the valve delivery system using the loading system
Access the aortic valve with the delivery catheter
Deploy the valve accurately across the native aortic valve
Remove the intact delivery system</description>
        <time_frame>Was assessed during the procedure and completed once the procedure was conlcluded</time_frame>
        <population>For two patients in the moderate risk group the composite technical device success could not be calculated because not all measurements required were available.</population>
        <group_list>
          <group group_id="O1">
            <title>High Risk With Complete Device Success Data</title>
            <description>Subjects with a high risk of operative mortality with all data available to calculate the composite technical device success</description>
          </group>
          <group group_id="O2">
            <title>Moderate Risk With Complete Device Success Data</title>
            <description>Subjects with a moderate risk of operative mortality with all data available to calculate the composite technical device success</description>
          </group>
          <group group_id="O3">
            <title>Overall Study</title>
            <description>All enrolled subjects for whom the procedure for percutaneous implantation of the Medtronic CoreValve aortic valve prosthesis was started.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Technical Device Success</title>
          <description>Composite technical success was defined as the percentage of subjects in whom success on all four technical measures of the &quot;Device Functionality Assessment&quot; was achieved and who were adjudicated as having no device failure or malfunction.
The four measures of the ''Device Functionality Assessment'' were:
Load the valve delivery system using the loading system
Access the aortic valve with the delivery catheter
Deploy the valve accurately across the native aortic valve
Remove the intact delivery system</description>
          <population>For two patients in the moderate risk group the composite technical device success could not be calculated because not all measurements required were available.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.7" lower_limit="74.3" upper_limit="92.1"/>
                    <measurement group_id="O2" value="80.8" lower_limit="67.5" upper_limit="90.4"/>
                    <measurement group_id="O3" value="83.1" lower_limit="75.3" upper_limit="89.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from date of implantation till 4 years follow up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Risk</title>
          <description>Overall study population was divided in high and moderate risk groups based on the risk of operative mortality. The risk classification was performed by 2 independent cardiovascular surgeons who were blinded to procedural details and outcomes but were provided with the baseline logistic EuroSCORE, baseline data and available source documentation.</description>
        </group>
        <group group_id="E2">
          <title>Moderate Risk</title>
          <description>Overall study population was divided in high and moderate risk groups based on the risk of operative mortality. The risk classification was performed by 2 independent cardiovascular surgeons who were blinded to procedural details and outcomes but were provided with the baseline logistic EuroSCORE, baseline data and available source documentation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="81" subjects_affected="47" subjects_at_risk="72"/>
                <counts group_id="E2" events="49" subjects_affected="34" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="72"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <description>Any other reported adverse events not assosiated with the use of the study device were collected without specyfying a specific adverse event term</description>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="72"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <counts group_id="E1" events="36" subjects_affected="23" subjects_at_risk="72"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="72"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="72"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="72"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="72"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="72"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="40" subjects_affected="32" subjects_at_risk="72"/>
                <counts group_id="E2" events="29" subjects_affected="19" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="72"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <counts group_id="E1" events="32" subjects_affected="24" subjects_at_risk="72"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="72"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="72"/>
                <counts group_id="E2" events="18" subjects_affected="12" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="32" subjects_affected="23" subjects_at_risk="72"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>M. Hollander</name_or_title>
      <organization>Medtronic</organization>
      <phone>+31620534428</phone>
      <email>maarten.hollander@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

